103535-06-4 Usage
Uses
Used in Organic Synthesis:
(2-BENZYLOXYETHYL)TRIPHENYLPHOSPHONIUM BROMIDE is used as a phase-transfer catalyst for facilitating reactions between immiscible reactants in organic synthesis. It aids in the transfer of ions to the organic phase, enhancing the efficiency and selectivity of various chemical reactions.
Used in Pharmaceutical Synthesis:
In the pharmaceutical industry, (2-BENZYLOXYETHYL)TRIPHENYLPHOSPHONIUM BROMIDE is used as a reagent in the synthesis of pharmaceuticals and other organic compounds. Its ability to act as a phase-transfer catalyst makes it a valuable tool in the development of new drugs and the improvement of existing ones.
Used in Chemical Research:
(2-BENZYLOXYETHYL)TRIPHENYLPHOSPHONIUM BROMIDE is also utilized in chemical research for studying reaction mechanisms and exploring new synthetic pathways. Its unique properties as a phase-transfer catalyst make it a valuable asset in advancing the field of organic chemistry.
Check Digit Verification of cas no
The CAS Registry Mumber 103535-06-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,0,3,5,3 and 5 respectively; the second part has 2 digits, 0 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 103535-06:
(8*1)+(7*0)+(6*3)+(5*5)+(4*3)+(3*5)+(2*0)+(1*6)=84
84 % 10 = 4
So 103535-06-4 is a valid CAS Registry Number.
103535-06-4Relevant academic research and scientific papers
Method for preparing eribulin and intermediate thereof
-
Paragraph 0110-0112, (2018/09/08)
The present invention relates to a method for preparing eribulin and an intermediate thereof. In particular, the invention relates to a method for preparing a compound of formula 5, R3 is selected from aldehyde or OR1, n=0 or 1, R1 is a hydroxy protecting group, and preferably the hydroxy protecting group is selected from tert-butyldimethylsilyl, tert-butyldiphenylsilyl, p-methoxybenzyl or benzyl.The invention also provides a method for preparing halichondrin and derivatives thereof such as the eribulin from the compound of formula 5.
CARBAMOYLOXYMETHYL TRIAZOLE CYCLOHEXYL ACIDS AS LPA ANTAGONISTS
-
Paragraph 0970-0972, (2018/01/18)
The present invention provides compounds of Formula (I): or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.
